Structure-Permeability Relationship of Semipeptidic Macrocycles-Understanding and Optimizing Passive Permeability and Efflux Ratio.


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
09 07 2020
Historique:
pubmed: 27 5 2020
medline: 18 11 2020
entrez: 27 5 2020
Statut: ppublish

Résumé

We herein report the first thorough analysis of the structure-permeability relationship of semipeptidic macrocycles. In total, 47 macrocycles were synthesized using a hybrid solid-phase/solution strategy, and then their passive and cellular permeability was assessed using the parallel artificial membrane permeability assay (PAMPA) and Caco-2 assay, respectively. The results indicate that semipeptidic macrocycles generally possess high passive permeability based on the PAMPA, yet their cellular permeability is governed by efflux, as reported in the Caco-2 assay. Structural variations led to tractable structure-permeability and structure-efflux relationships, wherein the linker length, stereoinversion, N-methylation, and peptoids site-specifically impact the permeability and efflux. Extensive nuclear magnetic resonance, molecular dynamics, and ensemble-based three-dimensional polar surface area (3D-PSA) studies showed that ensemble-based 3D-PSA is a good predictor of passive permeability.

Identifiants

pubmed: 32453569
doi: 10.1021/acs.jmedchem.0c00013
doi:

Substances chimiques

Macrocyclic Compounds 0
Membranes, Artificial 0
Peptides 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6774-6783

Auteurs

Antoine Le Roux (A)

Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada.

Émilie Blaise (É)

Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada.

Pierre-Luc Boudreault (PL)

Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada.

Christian Comeau (C)

Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada.

Annie Doucet (A)

Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada.

Marilena Giarrusso (M)

Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada.

Marie-Pierre Collin (MP)

Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany.

Thomas Neubauer (T)

Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany.

Florian Kölling (F)

Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany.

Andreas H Göller (AH)

Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany.

Lea Seep (L)

Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany.

Dieudonné T Tshitenge (DT)

Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany.

Matthias Wittwer (M)

Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany.

Maximilian Kullmann (M)

Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany.

Alexander Hillisch (A)

Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany.

Joachim Mittendorf (J)

Drug Discovery, Pharmaceuticals, Bayer AG, Wuppertal D-42096, Germany.

Eric Marsault (E)

Department of Pharmacology-Physiology, Institut de Pharmacologie de Sherbrooke, 3001, 12e av nord, Sherbrooke, Québec J1H 5N4, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH